Nabriva Therapeutics plc (NBRVF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNabriva Therapeutics plc (NBRVF) trades at $0.0001. Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections.
Price as of Sep 11, 2026 · Last analyzed: Sep 7, 2026Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007.
Analyst Coverage for NBRVF: NBRVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NBRVF against sector peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
NBRVF: the 2 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Nabriva Therapeutics plc Company Overview
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
NBRVF Current Price & Trading Activity
NBRVF is currently trading at $0.00, with a daily change of +0.00 (+0.00%). The stock has a trading volume of 780 shares, which provides insight into market interest and liquidity for this security.
Analyst Coverage for NBRVF
NBRVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model scores NBRVF on quantitative fundamentals — growth, financial health, valuation, and momentum — relative to sector peers and assigns a neutral fundamental signal based on the underlying data. Investors monitoring NBRVF should weigh peer-relative metrics and sector momentum more heavily until institutional coverage emerges.
Data sourced from Financial Modeling Prep, Yahoo Finance and SEC EDGAR. This content is generated from market data and is not financial advice. Past performance does not guarantee future results.
NBRVF Latest News
No recent news available for NBRVF.
NBRVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NBRVF.
Price Targets
Wall Street price target analysis for NBRVF.
NBRVF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NBRVF; grades run from A+ (80-100) to F (below 30).
NBRVF OTC Market Information
NBRVF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Investor Questions: NBRVF Stock
Is NBRVF a good stock?
Stock Expert AI does not rate NBRVF buy, sell or hold. Nabriva Therapeutics plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for NBRVF?
Evaluate NBRVF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does NBRVF data refresh on this page?
NBRVF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NBRVF's recent stock price performance?
Nabriva Therapeutics plc (NBRVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NBRVF overvalued or undervalued right now?
Nabriva Therapeutics plc (NBRVF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of NBRVF?
Yes, most major brokerages offer fractional shares of Nabriva Therapeutics plc (NBRVF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track NBRVF's earnings and financial reports?
Nabriva Therapeutics plc (NBRVF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for NBRVF earnings announcements.
What should investors new to NBRVF understand first?
Nabriva Therapeutics plc (NBRVF) is worth researching across volatility, fundamentals, and industry context. With a market cap of $323, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.